

- In 2022 IPS continued its BPP Special Project called "Industrial Pharmacists in Industry".
 - The project effectively started in October 2021, aimed to determine what "valueadded" role a pharmacist can play in the pharmaceutical industry; and hence promote the employment of the pharmacist within the pharmaceutical industry.
 - 400 participants from 40 different countries responded to the IPS online questionnaire until end of December 2022, meeting the IPS target for data assessment. Despite all continents are represented, most repliers were from Africa and Asia (India).
 - IPS decided to open questionnaire again through 2023 (funded by IPS), aimed to receive more contributions from US and EU countries.
 - o 97.25% (391 participants/400) supported that employing a pharmacist in industry, add value to the company, against 2.25% (9 participants/400) of NO.
 - 50.69% responded that there is a trend to deregulate the pharmaceutical profession in their countries, and open jobs previously restricted to pharmacists to other professionals.
 - o The initial budget given by BPP, allocated for this project was 2000€, but this amount was reviewed to 4400€ approved by the IPS ExCo, due to the increased amount of the work and extra expenses with online campaign management.
 - Four (04) voluntary ECPG (formerly YPG) members assisted the IPS working group, by writing articles, reports and helping in data analysis.
- Status of **2022 IPS Goals** (set in the last Annual Report):
 - o Goal #1: Develop the BPP Special Project "Industrial Pharmacists in Industry"

<u>Status</u>: IPS completed its BPP Special Project, and results were presented to IPS ExCo, FIPEd and final report shared with FIP BPP. (See key results abovementioned in IPS achievements).

 Goal #2: Increase social media numbers of IPS by 25% and engage with other Sections under the One-FIP concept.

Status:

The IPS LinkedIn account posted 34 times throughout 2022 which achieves the goal of regular posting over the year, establishing continuous communication of IPS activities.

10 of 34 posts were related to connection with the profiles of other FIP sections and other industrial institutions, for mutual promotion of events and engagement: Examples include promoting posts from FIP HQ, promoting job opportunities and congresses of prominent institutions (EFPIA, Uppsala Monitoring Centre), promoting the FIP Congress and participating in the World Pharmacist's Day campaign.

18 of 34 posts promoted IPS webinars in multiple languages. Dedicated pages were created where attendees engaged with each other and IPS.

In 2022, IPS increased promotion of its active members and projects, with 7 of 34 posts in total, relating to IPS' BPP Special Project (survey), new elected IPS ExCo members and awards that honoured IPS members around the world.

As of December 2022, the IPS page on LinkedIn has exceeded 1000 followers, with the current number being 1019 followers (February 2023), compared to the 703 followers counted in 2021.

 Goal #3: Improve IPS outreach to different regions by translating webinars into multiple languages.

<u>Status</u>: IPS organized **5 Webinars** in 2022, most of them provided with multilanguage simultaneous translation (Mandarin, Spanish, English and Portuguese.

March: FDA (CDER): Generic Development and Bridging Global Regulations Description. Sarah Ibrahim, FDA CDER.

- 936 registrations
- 464 attendees, from 80 countries

April: Clinical Evaluation on Large Volume Subcutaneous Injection - Tissue effects, Pain, and Acceptability in Healthy Adults. Wendy D Woodley, Scientist at Translational & Clinical Sciences at BD Technologies and Innovation, USA.

- 317 registrations
- 260 attendees, from 41 countries

June: Expedited Regulatory Pathways – Possible in Developing Countries with Strong Reliance Practices and Post-Authorization Surveillance Systems. Jude Nwokike, Vice-President at US Pharmacopeia.

- 604 registrations
- 236 attendees, from 59 countries

October: **RNA-based medicines for Unmet Medical Needs.** Olivia Merkel from LMU, Germany.

- 577 registrations
- 214 attendees, from 51 countries

November: **The Patient Voice in Generic Medicine Development.** Dr. Sarah Ibrahim, Associate Director CDER of the US FDA will be presenting the FDA's perspectives on the role of patient engagement in drug development.

- 301 registrations
- 116 attendees, from 45 countries
- Four issues of the "quarterly" **IPS Newsletter** were delivered to the Section's members in 2022, including special editions dedicated to IPS Virtual Assembly.
- Virtual IPS ExCo Assembly and IPS ExCo Elections occurred in August 29th, 2022.
 - Filipa Ferreira (Portugal), Forum R. Gandhi (Jalundhwala) (India) and Kaushik Desai (India) were elected to the Executive Committee of IPS, with terms starting on January 1st, 2023.
- On August 2nd, members of the IPS ExCo participated in the 2nd ECPG (former YPG)
 Networking Event with the Health and Medicines Information Section (HaMS) and the
 Industrial Pharmacy Section (IPS).
- IPS continued conversations with two institutions in Latin America (LATFAR and SINDUSFARMA, respectively) aimed to increase the regional participation of FIP/IPS in Latin America, through the development of regional events (virtual and presential). With Sindusfarma, IPS had agreed to resume the annual symposium in cooperation with ANVISA, the health agency of Brazil.
- IPS currently has representation in all FIP SIGs and Regional Forums. At least one ExCo
 member is aimed to attend to these meetings and engage with them to cooperate in the
 subjects with relevant to industrial professionals.

Please highlight <u>one</u> activity that your Section is particularly proud of and explain how it relates to the FIP mission and vision (<u>https://www.fip.org/vision-mission</u>) and the FIP Development Goals (<u>https://www.fip.org/search?page=fip-development-goals</u>).

- The 2022 series of IPS multilingual webinars took part in FIP's Digital Events calendar. They
 supported pharmacists in their career development, knowledge enrichment and networking
 year-round and deep correlate with:
 - FIP Development Goals:
 - Goal 3 (Quality Assurance)

- Goal 4 (Advanced and Specialist Development)
- Goal 8 (Working with Others)
- Goal 9 (Continuing Professional Development Strategies)
- Goal 14 (Medicine Expertise)
- o FIP's vision and mission, in the sense that by providing multilingual relevant training to industrial pharmacists through digital platform, IPS enables the advance of pharmaceutical practice in different regions and promotes the access to safe, effective, quality, and affordable medicines and health technologies across the globe.

Goals in 2023:

- Goal #1: Social Media: to increase number of followers of IPS webpages by 10%
- Goal #2: Special Project "Industrial Pharmacists in Industry": to progress the BPP Special Project lead by IPS to next stage:
 - Continue online survey until the 2023 FIP Congress (Brisbane), aiming to increase the number of respondents from North America and Europe;
 - o Collaborate with GPO and FIPEd to identify gaps in pharmaceutical curriculum; and
 - Develop plans to close gaps.
- Goal #3: GMP Training: to organize a continuing education training on Good Manufacturing Practices at the 2023 FIP Congress (Brisbane).

Part B: Input into the 2022 FIP annual report

The FIP annual report covers activities from January to December 2022. The provisional theme of the annual report this year is: "One FIP: United for a healthier world".

FIP HQ would like to highlight selected Section activities in its annual report. To facilitate effective integration of your accomplishments in this report, please fill in the box below.

As well as being a promotional tool, an annual report can be used as an internal document to record achievements as well as challenges. You may consider acknowledging substantial contributions of individuals who were instrumental in initiating/completing important tasks relevant to your Section members. In addition, to recognising and thanking people, an annual report can also serve as a medium to motivate and inspire people to contribute to the goals of the Board of Pharmaceutical Practice (BPP).

• In two or three sentences, please highlight <u>one</u> activity that relates to the provisional theme of the annual report "**One FIP: United for a healthier world**" and describe its impact/outcomes. We greatly appreciate quantitative information if available.

The IPS actions in social media: about a third of all IPS posts (10 of 34) were related to connection with the profiles of other FIP sections and other industrial institutions, for mutual promotion of events and engagement. Examples include promoting posts from FIP HQ, job opportunities, congresses of prominent institutions (EFPIA, Uppsala Monitoring Centre), FIP Congress and participating in the World Pharmacist's Day campaign.

 For the above activity, please provide a positive quote that can be used in the annual report. This quote could be from a person within or external to FIP. It should say something good about FIP/the Section and why the activity was beneficial. It should reflect well on FIP's work without being overly promotional.

Quote:

"IPS supports FIP's development goals of learning and development of pharmacy profession through series of activities conducted on digital platform benefitting industrial pharmacists on their knowledge enrichment and career growth and keeping them abreast about new developments."

Person's name, including title (Prof, Dr, Mr, Mrs, Ms): Mr. Kaushik Desai His or her job/role title: IPS ExCo member / Pharmaceutical Consultant (India) Email address (so we can contact for a photo if needed): kaushikdesai10@gmail.com

(For example, in the 2014 annual report (p. 14), the signing of a memorandum of understanding between FIP and Monash University was mentioned. So for the activity (the signing of memorandum), the form would be as follows:

Quote: "Monash University is thrilled to partner with FIP as a means to broaden the reach and scope of the SABER platform to support pharmacy teaching and learning environments through the auspices of FIP."

Person's name, including title (Prof, Dr, Mr, Mrs, Ms): Prof Bill Charman
His or her job/role title: Dean of the Faculty of Pharmacy and Pharmaceutical Sciences, Monash
University, Melbourne, Australia
Email address (so we can contact for a photo if needed): Bill.Charman@......)

Last year's annual report is accessible at <a href="https://www.fip.org/publications?publicationCategory=18&publicationYear=&publicationKeyword="publicationKeyword="https://www.fip.org/publications?publicationCategory=18&publicationYear=&publicationKeyword="publicat